Locked Nucleic Acid
(LNA™) Phosphoramidites
Locked Nucleic Acid (LNA) was first described1 by Wengel and co-workers in 1998 as a novel class of conformationally
restricted oligonucleotide analogues, possessing very high affinity and excellent specificity toward complementary DNA and RNA2. LNA molecules have been used to improve design and efficacy of oligonucleotides directed at regulating gene expression, for example, antisense and siRNA. Incorporating LNA into oligonucleotides has positive effects on delivery to cells, stability, non-specific effects, toxicity, and pharmacokinetics. LNA can also be used to develop more efficient diagnostic tools, for example, probes in genotyping3 and in DNA array design4. Because of their increased affinity, LNA containing probes can be shortened and this is particularly attractive for miRNA expression research5. These properties are detailed in several reviews6.
| 10-2000-90 |
100 µmole |
120.00 |
| |
10-2000-02 |
0.25g |
225.00 |
| |
10-2000-05 |
0.5g |
450.00 |
| 10-2011-90 |
100 µmole |
120.00 |
| |
10-2011-02 |
0.25g |
225.00 |
| |
10-2011-05 |
0.5g |
450.00 |
| 10-2029-90 |
100 µmole |
120.00 |
| |
10-2029-02 |
0.25g |
225.00 |
| |
10-2029-05 |
0.5g |
450.00 |
| 10-2030-90 |
100 µmole |
120.00 |
| |
10-2030-02 |
0.25g |
225.00 |
| |
10-2030-05 |
0.5g |
450.00 |
|
References
(1a) A.A. Koshkin, S.K. Singh, P. Nielsen, V.K. Rajwanshi, R. Kumar, M. Meldgaard, C.E. Olsen, and J. Wengel, Tetrahedron,1998, 54, 3607-3630.
(1b) S.K. Singh, P. Nielsen, A.A. Koshkin, and J. Wengel, Chem. Comm., 1998, (4), 455-456.
(2) L. Kværnø and J. Wengel, Chem. Comm., 1999, (7), 657-658.
(3) L.A. Ugozzoli, D. Latorra, R. Puckett, K. Arar, and K. Hamby, Anal Biochem, 2004, 324, 143-52.
(4) J.P. Liu, et al., Comb Chem High Throughput Screen, 2006, 9, 591-7.
(5) M. Castoldi, et al., RNA, 2006, 12, 913-20.
(6a) D.A. Braasch, D.R. Corey, Biochemistry, 2002, 41, 4503-4510.
(6b) J.S. Jepsen, M.D. Sorensen, and J. Wengel, Oligonucleotides, 2004, 14, 130-146.
(6c) B. Vester, and J. Wengel, Biochemistry, 2004, 43, 13233-41.
INTELLECTUAL PROPERTY
Locked-nucleic Acid (LNA) phosphoramidites
are protected by EP Pat No. 1013661, US Pat No. 6,268,490 and foreign
applications and patents owned by Exiqon A/S. Products are made and sold
under a license from Exiqon A/S. Products are for research purposes only.
Products may not be used for diagnostic, clinical, commercial or other
use, including use in humans. There is no implied license for commercial
use, including contract research, with respect to the products and a license
must be obtained directly from Exiqon A/S for such use.
|
Caps for Increased
Duplex Stability and Base-Pairing Fidelity at Termini
New cap structures allow for the preparation of hybridization
probes with increased affinity for complementary sequences. The monomers
used to prepare capped oligonucleotides are phosphoramidites that can
be readily introduced via automated DNA synthesis at the end of solid
phase syntheses. The caps favor the formation of stable Watson-Crick duplexes
by stacking on the terminal base pair (Figure 1).
|
FIGURE 1: STACKING OF CAP ON TERMINAL BASE PAIR |
Melting point increases of over 10 °C per modification
can be realized for short duplexes.1,2 The caps fit canonical Watson-Crick
base pairs and do not stack well on mismatched base pairs. This leads
to increased base pairing selectivity at the terminal and the penultimate
position of oligonucleotides featuring the caps. Base pairing fidelity
is usually low at the termini, where fraying occurs frequently in the
absence of caps. The beneficial effects of the caps are also realized
when longer target strands are bound, so there is no need for blunt ends
for the duplexes formed.1,2 The caps, when attached to the terminus of
an oligonucleotide, also facilitate purification as their lipophilicity
leads to prolonged retention on reversed phase columns or cartridges.
Finally, capping of termini may discourage the degradation of oligonucleotides
by exonucleases.
| 10-1986-90 |
100 µmole |
195.00 |
| |
10-1986-02 |
0.25g |
495.00 |
| 10-1987-90 |
100 µmole |
195.00 |
| |
10-1987-02 |
0.25g |
495.00 |
|
References
(1) Dogan, Z.; Paulini, R.; Rojas Stütz, J. A.;
Narayanan, S.; Richert, C. J. Am. Chem. Soc. 2004, 126, 4762-4763.
(2) Narayanan, S.; Gall, J.; Richert, C. Nucleic Acids Res. 2004, 32,
2901-2911.
|